Navigation Links
ANAVEX completes scale-up manufacturing of ANAVEX 2-73 for Phase I Alzheimer's disease clinical trials
Date:9/21/2009

GENEVA, Sept. 21 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

"With sufficient quantities of ANAVEX 2-73 in hand we are an important step closer to the commencement of Phase I clinical trials, which are scheduled to begin in early 2010," said Dr. Herve de Kergrohen, CEO of ANAVEX. "This lead drug candidate shows potential to alter the course of Alzheimer's disease by using sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease."

ANAVEX will shortly announce the selection of the Contract Research Organization (CRO) in charge of carrying out its Phase I clinical trials. Phase I is the stage at which testing moves to humans. Trials are designed to confirm the drug's safety and determine its tolerability in humans. Pharmacokinetics (the mechanisms of absorption and distribution of the drug, the rate at which a drug begins to act and the duration of its effect, as well as chemical changes of the substance in the body) and pharmacodynamics (physiological effects of drugs on the body, mechanisms of action and relationship between drug concentration and effect) are also studied during Phase I. ANAVEX 2-73 has already demonstrated powerful neuroprotective, anti-amnesic, anti-convulsive and anti-depressive activity in animal models. It also exhibited an excellent safety profile and therapeutic activity at very low doses.

The two kilograms of ANAVEX 2-73 was manufactured by Syntagon AB ("Syntagon") under GMP conditions, the quality assurance system required in the production of medicinal products. Syntagon developed a five-step synthetic procedure that achieved excellent yields in terms of the quantity of the compound that was produced and delivered it to ANAVEX on time.
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimers Disease 2008
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
4. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
5. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
6. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
7. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
8. SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
9. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
10. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... , Oct. 20, 2014   BioNano Genomics ... system: the ability to collect human data at 30X depth, ... single chip.  This new capability was established and demonstrated for ... Irys TM System and will be rolled ... months. BioNano will be showcasing this advancement at the ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5ResMed Launches ResMed Data Exchange 2BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3
... MISSISSAUGA, Ontario, June 14, 2011 Theramed Corporation ... jetty™ at the 67th Clinical Meeting of the Society ... developed medical devices are to be used to advance ... Both medical device products have been approved for sale ...
... the 2011 Society of Gastroenterology Nurses and Associates (SGNA) ... PA) presented the results of a study evaluating the ... organic soils remaining in flexible endoscopes after cleaning. ... (Healthmark Industries Company, Inc., Fraser, Michigan) is to test ...
Cached Medicine Technology:Theramed Corporation to Launch Glenveigh Products, ebb™ and jetty™ at the Society of Obstetricians and Gynecologists of Canada 2Flexible Endoscope Manufacturer Determines Test Suitable for Evaluating Cleanliness of Flexible Endoscopes 2
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... Complimentary Continuing Medical Education Virtual Lecture and Podcast ... Clostridium difficile infection (CDI) is changing ... more severe and complicated disease. Furthermore, the epidemic ... number of states across the United States, and ...
... Corporation (NYSE: CVS ) today announced ... Officer and Chief Administrative Officer, will be making ... Institutional Investors Conference on March 10, 2009. Mr. ... a.m. EDT. (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO )An ...
... Supplement Offers Promising Results for Tired Baby ... Ribose Company(TM)--has announced preliminary findings indicating that ... The results were presented at the Scripps ... and is a patented functional ingredient for ...
... Diabetes patients undergoing team-based care do not save ... than other patients, but they are healthier, according ... a substantial financial burden on patients, payers and ... and administration, Penn State, and lead author of ...
... new article appearing in the March 2009 issue of ... ) may lead to improvements in the efficacy of ... researchers discovered a new role for type I interferon, ... to stimulate an immune response against the bacterium known ...
... It might one day be used as an ingredient in ... Past studies have suggested that caffeine might offer some protection ... "We have found what we believe to be the mechanism ... lead researcher Dr. Paul Nghiem, an associate professor of dermatology ...
Cached Medicine News:Health News:Interview with GI Experts: Discussions in Clostridium difficile 2Health News:CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th 2Health News:Bioenergy Ribose Found to Improve Vitality, Aerobic Fitness and Mental Outlook 2Health News:Bioenergy Ribose Found to Improve Vitality, Aerobic Fitness and Mental Outlook 3Health News:Team-based diabetes care fetches more value for dollar 2Health News:New discovery gives tuberculosis vaccine a shot in the arm 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3
... Control is a human ... provides the laboratory with ... for lipids analysis. It ... in levels optimized for ...
Liquichek Pediatric Control is a product designed to monitor important analytes for neonatal testing. This control monitors four bilirubin parameters at two clinically significant levels....
Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
Lyphochek® Drug Free Serum can serve as a drug-free baseline for HPLC analysis or as a negative control....
Medicine Products: